ImageneBio (IMA) Accounts Payables (2020 - 2025)
ImageneBio (IMA) posted Accounts Payables of $1.4 million for Q4 2025, down 30.85% sequentially from $2.1 million in Q3 2025, and down 72.8% YoY from $5.3 million in Q4 2024.
ImageneBio (IMA) Accounts Payables (2020 - 2025) Analysis & Trends
ImageneBio has reported Accounts Payables for 6 years, with the latest figure at $1.4 million in Q4 2025.
- Quarterly Accounts Payables fell 72.8% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (down 72.8% YoY) and the FY2025 annual result came in at $1.4 million, down 72.8% from the prior year.
- Accounts Payables slipped to $1.4 million in Q4 2025 per IMA's latest filing, from $2.1 million in the prior quarter.
- Over five years, Accounts Payables peaked at $5.3 million in Q4 2024 and troughed at $512000.0 in Q2 2025.
- A 5-year average of $2.3 million and a median of $2.1 million in 2022 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables surged 156.05% in 2024, then plunged 72.8% in 2025.
- Over 5 years, Accounts Payables stood at $2.4 million in 2021, then retreated by 12.21% to $2.1 million in 2022, then dropped by 1.29% to $2.1 million in 2023, then jumped by 156.05% to $5.3 million in 2024, then slumped by 72.8% to $1.4 million in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.4 million, $2.1 million, and $512000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | ImageneBio | 47.79 Mn | -87.56 Mn | - | 1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.44 Mn |
| Sep 30, 2025 | 2.08 Mn |
| Jun 30, 2025 | 512,000.00 |
| Mar 31, 2025 | 805,000.00 |
| Dec 31, 2024 | 5.29 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Mar 31, 2024 | 1.91 Mn |
| Dec 31, 2023 | 2.07 Mn |
| Sep 30, 2023 | 3.95 Mn |
| Jun 30, 2023 | 1.77 Mn |
| Mar 31, 2023 | 2.76 Mn |
| Dec 31, 2022 | 2.09 Mn |
| Sep 30, 2022 | 2.36 Mn |
| Jun 30, 2022 | 4.09 Mn |
| Mar 31, 2022 | 2.39 Mn |
| Dec 31, 2021 | 2.38 Mn |
| Sep 30, 2021 | 1.93 Mn |
| Jun 30, 2021 | 2.47 Mn |
| Mar 31, 2021 | 2.53 Mn |